Point-Of-Care International Normalized Ratio (INR) Testing Market Forecast Signals New Revenue Opportunities Through 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Point-Of-Care International Normalized Ratio (INR) Testing Market Expected To Reach $2.56 Billion By 2030 At 10.1% CAGR
The point-of-care inr testing market size has experienced rapid expansion recently. It is anticipated to grow from $1.58 billion in 2025 to $1.75 billion in 2026, at a compound annual growth rate (CAGR) of 10.4%. Historically, this growth was driven by factors such as the increasing prevalence of cardiovascular diseases, the growing adoption of anticoagulant therapy, a rising incidence of atrial fibrillation, the expansion of outpatient and homecare settings, and an increasing demand for rapid coagulation testing.
The point-of-care inr testing market is projected for swift expansion over the coming years. Its valuation is anticipated to reach $2.56 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.1%. This growth during the forecast period is primarily driven by an escalating demand for at-home monitoring solutions, the expanding elderly demographic receiving long-term anticoagulation therapy, an intensifying emphasis on individualized anticoagulation management, the proliferation of decentralized healthcare frameworks, and greater integration into primary care settings. Key trends projected for this period encompass technological enhancements in portable coagulation analysis devices, breakthroughs in biosensor and microfluidic advancements, progress in wireless connectivity and data integration capabilities, ongoing research and development into highly accurate test strips, and improvements in smartphone-assisted inr testing.
Download A Free Sample Report For Comprehensive Market Insights:
#Point-Of-Care International Normalized Ratio (INR) Testing Market Demand Drivers Creating New Revenue Opportunities
The increasing occurrence of heart-related ailments is projected to boost the expansion of the point-of-care International Normalized Ratio (INR) testing market in the future. These conditions encompass diseases impacting the heart and blood vessels, such as cardiac arrests, cerebrovascular accidents, and high blood pressure. The rise in cardiovascular diseases is attributable to unhealthy habits like inadequate nutrition, insufficient physical activity, and tobacco use. Point-of-care International Normalized Ratio (INR) testing assists in diagnosing cardiovascular conditions by allowing for quick evaluation of blood clotting at patient’s side or in a clinical setting. This method enhances medical decision-making through its capacity for prompt identification of coagulation irregularities and for directing anticoagulant treatments. For example, data from the Centers for Disease Control, a US-based government entity, indicated that in October 2024, around 919,032 individuals succumbed to cardiovascular disease in 2023, representing 1 in every 3 fatalities. Consequently, the growing incidence of cardiovascular illnesses is fueling the expansion of the point-of-care International Normalized Ratio (INR) testing market.
Point-Of-Care International Normalized Ratio (INR) Testing Market Segmentation And Category Breakdown
The point-of-care international normalized ratio (inr) testing market covered in this report is segmented –
1) By Product Type: Devices, Consumables, Software
2) By Technology: Electrochemical, Optical, Others
3) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Or E-Commerce, Others
4) By Application: Hospitals, Clinics, Home Care, Diagnostic Centers, Others
5) By End-User: Healthcare Professionals, Patients
Subsegments:
1) By Devices: Portable Testing Devices, Handheld Testing Devices, Desktop Testing Devices
2) By Consumables: Test Strips, Cartridges, Control Solutions
3) By Software: Data Management Software, Remote Monitoring Software, Analytical Software
Point-Of-Care International Normalized Ratio (INR) Testing Market Trends Driving Strategic Industry Expansion
Companies operating in the point-of-care International Normalized Ratio (INR) testing market are concentrating on developing sophisticated products, such as patient self-monitoring coagulation analyzers, to expand decentralized testing and redirect recurring demand towards lower-cost consumables. These patient self-monitoring coagulation analyzers are portable devices that enable individuals to perform PT/INR testing at home using a small capillary blood sample, thereby supporting frequent monitoring and reducing the need for clinical visits. For instance, in March 2024, Universal Biosensors, an Australia-based medical device company, introduced the Xprecia Prime 4U Coagulation Analyzer specifically for patient self-monitoring. This self-monitoring coagulation analyzer is designed to fit in the palm of the hand, delivers rapid PT/INR results from just one drop of capillary blood, and employs an electrochemical strip format that supports various regulatory approvals, including 510(k) clearance and CLIA waiver for the U.S. market. This launch represents a significant stride in INR testing by facilitating wider access to home monitoring, increasing the frequency of tests, and improving cost efficiency through enhanced consumable utilization, all while maintaining clinical accuracy.
Point-Of-Care International Normalized Ratio (INR) Testing Market Competitive Analysis Of Major Industry Participants
Major companies operating in the point-of-care international normalized ratio (inr) testing market are Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton, Dickinson and Company, Hoffmann-La Roche Ltd., QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Werfen S.A., HORIBA Ltd., Microvisk Ltd., Randox Laboratories Ltd., Nova Biomedical Corporation, Agappe Diagnostics Ltd., Visby Medical Inc., EKF Diagnostics Holdings plc, Trinity Biotech plc, HemoSonics LLC, Human Diagnostics Worldwide GmbH, CoaguSense Inc.
Access The Complete Point-Of-Care International Normalized Ratio (INR) Testing Market Report:
Point-Of-Care International Normalized Ratio (INR) Testing Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the Point-of-Care INR Testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care international normalized ratio (inr) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
